Currently out of the existing stock ratings of Akash Tewari, 95 are a BUY (76.61%), 25 are a HOLD (20.16%), 4 are a SELL (3.23%).

Akash Tewari

Work Performance Price Targets & Ratings Chart

Analyst Akash Tewari, currently employed at JEFFERIES, carries an average stock price target met ratio of 48.81% that have a potential upside of 26.64% achieved within 195 days.

Akash Tewari’s has documented 235 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ENTA, Enanta Pharmaceuticals at 30-Sep-2025.

Wall Street Analyst Akash Tewari

Analyst best performing recommendations are on ARVN (ARVINAS).
The best stock recommendation documented was for ARVN (ARVINAS) at 6/21/2022. The price target of $42 was fulfilled within 2 days with a profit of $3.11 (8%) receiving and performance score of 39.98.

Average potential price target upside

of $121.85 (19.07%) on LLY (ELI LILLY AND COMPANY).
of $99.73 (61.3%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $84.01 (18.89%) on ARGX (ARGENX NV ADR).

ALKS Alkermes Plc CYTK Cytokinetics EXEL Exelixis XLRN Acceleron Pharma BMRN Biomarin Pharmaceutical ENTA Enanta Pharmaceuticals ARGX argenx NV ADR BNTX BioNTech SE GBT Global Blood Therapeutics MDGL Madrigal Pharmaceuticals EQRX EQRx REGN Regeneron Pharmaceuticals ZYME Zymeworks Common Stock LLY Eli Lilly and Company RLAY Relay Therapeutics PFE Pfizer HZNP Horizon Pharma PLC ARVN Arvinas JAZZ Jazz Pharmaceuticals PLC TERN Terns Pharmaceuticals MRK Merck mpany ZNTL Zentalis Pharmaceuticals Llc APLS Apellis Pharmaceuticals BMY Bristol-Myers Squibb Company NBIX Neurocrine Biosciences APGE Apogee Therapeutics, Common Stock SLRN ACELYRIN, INC. Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jessica Fye (JPMORGAN)